HSV 2 Inhibition Interpretation

A positive herpes antibody screen can be wrong, especially when the screening signal is weak or your likelihood of infection is low. HSV-2 inhibition interpretation is a supplemental result used to help resolve that uncertainty. Confirmation improves confidence, but no antibody test makes every result certain. FDA guidance

That distinction matters because an infection diagnosis can affect relationships, treatment decisions, and pregnancy care. A false-positive diagnosis can bring those consequences to someone who isn't infected. The evidence for routine screening of people without symptoms remains unfavorable, even though confirmation is useful once a screening result needs resolving. USPSTF recommendation

What the Inhibition Step Checks

HSV-2 is herpes simplex virus type 2. IgG antibodies are immune proteins that develop after infection and can persist for years. Type-specific herpes antibody tests commonly target glycoprotein G. This viral surface protein differs between HSV-1 and HSV-2, allowing tests to distinguish the two antibody responses. CDC laboratory documentation

Published studies of this inhibition approach used serum collected from blood samples. Separate portions were exposed to material from HSV-1-infected and HSV-2-infected cells before antibody binding was assessed. A reduction in binding specific to the HSV-2 preparation supports the presence of HSV-2-specific antibodies. This checks the specificity of antibody binding; it doesn't measure how effectively your immune system prevents outbreaks. Hogrefe et al.

• Positive: the assay identifies HSV-2-specific antibody reactivity, supporting an HSV-2 infection diagnosis.
• Negative: the screening reaction was not confirmed as HSV-2-specific, suggesting a false-positive screen.
• Indeterminate: interference prevents the lab from establishing whether HSV-2-specific antibodies are present.

These are qualitative categories. The interpretation has no level to optimize or trend. The percentage inhibition and screening index, if reported separately, describe different parts of the laboratory analysis. Inhibition assay interpretation

Why Screening Positives Need a Second Look

The chance that a positive screen is correct depends on the screening platform, the strength of its signal, and how common infection is in the tested population. A comparison of automated assays found substantial differences between platforms. Screening performance figures cannot be treated as accuracy estimates for the inhibition interpretation itself. Crawford et al.

A strong screening signal also doesn't guarantee infection. A separate study found false-positive and indeterminate inhibition results among specimens with higher screening indices. Confirmation can therefore be useful for an unexpected positive even when the original signal isn't weak. Prince et al.

Why Some Results Remain Unresolved

In the large laboratory study, indeterminate inhibition results were associated with stronger HSV-1 screening signals. But some indeterminate specimens had no detectable HSV-1 antibodies, and HSV-1 positivity did not explain negative inhibition results. This association cannot establish the cause of an individual unresolved result, and a screening index isn't a direct measure of antibody concentration. Shates et al.

An indeterminate inhibition result also differs from a report saying inhibition could not be performed. Sometimes a specimen that screened positive has too little reactivity on the platform used for confirmation to calculate inhibition. The laboratory's accompanying comment distinguishes these situations. Neither is a confirmed positive. Laboratory explanation

What a Confirmed Infection Means

HSV-2 infection is lifelong, though many people have mild symptoms or never recognize an outbreak. A modelling study adopted by WHO estimates that about 520 million people aged 15 to 49 had HSV-2 in 2020. HSV-1 usually causes oral herpes but can also cause genital infection. WHO fact sheet

Although an antibody result doesn't directly locate the virus, confirmed HSV-2 antibodies generally imply genital or anal infection. The result cannot identify when you acquired it, which partner transmitted it, or whether you are shedding virus today. HSV-1 antibodies are less informative about location because oral infection is so common. CDC guidance

People without recognized outbreaks can still release virus from genital skin and transmit it. A study using daily genital swabs found shedding less often among people without a history of symptoms, including on days without visible sores. Those swabs measured viral DNA, a different biological signal from the antibodies assessed by inhibition. Tronstein et al.

HIV Risk

Established HSV-2 infection is associated with roughly two to three times the risk of acquiring HIV. The risk is higher, around five times in pooled studies, in the period after HSV-2 is newly acquired. Your absolute risk still depends on exposure to HIV and the prevention measures you use. An inhibition result cannot estimate your personal HIV risk or establish whether you have HIV. CDC guidance

Pregnancy and Newborns

Herpes can pass to a baby during delivery and cause severe illness. The risk is greatest when genital infection is acquired late in pregnancy; it is much lower with an established infection. Delivery decisions depend on the timing of infection and symptoms or lesions around labor. A positive antibody result alone does not mean you need a cesarean delivery. ACOG guidance

Meningitis

HSV-2 can occasionally cause inflammation of the lining around the brain and spinal cord. A Danish nationwide study found that this meningitis most often affected younger women and could leave persistent symptoms. Blood antibodies cannot diagnose this complication; the assessment relies on symptoms and testing of spinal fluid. Jakobsen et al.

Rare inherited defects in antiviral defenses have been described in people with recurrent HSV-2 meningitis, with supporting experiments in their cells. These findings concern unusual severe disease and do not make a positive inhibition result evidence of an inherited immune disorder. Hait et al., Reyahi et al.

The Window Period and False Negatives

Antibodies take time to develop. Studies of other serum HSV-2 antibody assays found that the time to detection varied substantially by platform and prior HSV-1 infection. Those findings explain why early blood testing can miss infection, but they do not establish a precise detection window for this inhibition interpretation. Morrow et al.

False negatives can also occur in established infection. In a Dutch study, individual commercial antibody tests missed about 15% to 30% of 33 people with recurrent HSV-2 confirmed by DNA testing of genital lesions. These were screening antibody assays, not inhibition testing. The finding explains why a negative blood result does not overturn a positive lesion test. van Rooijen et al.

Screening values can fluctuate too. In a small study of long-standing HSV-2 infection, seven of 32 participants had at least one low-positive screening value, and one temporarily tested negative. Changes in the index could not reliably distinguish recent from established infection. Morrow et al.

When Results Can Be Misleading

• Recent exposure: an antibody response may still be developing. A negative result early after infection can be falsely reassuring. CDC testing information
• Interference during inhibition: reactivity with the HSV-1 preparation can prevent a clear interpretation. It doesn't prove that HSV-1 explains the original positive. Shates et al.
• Different laboratory methods: screening assays, inhibition, and Western blot can disagree. A study in young Kenyan men found substantial disagreement between inhibition and Western blot; it did not establish that either method was correct in every disputed specimen. Its accuracy figures should not be applied to everyone tested elsewhere. Smith et al.
• Treatment during a first infection: systemic acyclovir delayed the development of some HSV antibodies in an older trial. That study measured antibodies to different viral proteins, so the size of any effect on this inhibition result is unknown. Ashley and Corey
• Reading antibody strength as disease activity: screening indices and inhibition percentages are laboratory signals. They cannot establish when infection occurred or measure current shedding. Morrow et al.